PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-8.26%
Both companies show declining cash positions (-8.26% vs AGEN's -48.43%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-8.26%
Below half of AGEN's -48.43%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Below half of AGEN's -42.35%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-11.00%
≥ 1.5x AGEN's -1.69%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.61%
Below half of AGEN's -100.00%. Michael Burry sees possible underinvestment in long-term assets. Verify capital constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.27%
≥ 1.5x AGEN's -2.93%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
Similar yoy to AGEN's -7.48%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
18.31%
1.1-1.25x AGEN's 15.81%. Bill Ackman wonders if the firm relies on extended payables to manage cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.93%
1.25-1.5x AGEN's 12.61%. Martin Whitman is wary of bigger short-term burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.43%
Less than half of AGEN's -83.01%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
2.45%
Less than half of AGEN's -44.90%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.76%
1.25-1.5x AGEN's -1.27%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.00%
Below half AGEN's 69.95%. Michael Burry sees potential underperformance in building shareholder capital.
-8.20%
Similar yoy to AGEN's -7.48%. Walter Schloss sees parallel expansions in total capital.
0.61%
Below half AGEN's -100.00%. Michael Burry suspects major underinvestment or forced divestment.
-9.98%
Less than half of AGEN's -41.99%. David Dodd sees less overall debt expansion vs. competitor.
8.22%
Less than half of AGEN's -40.37%. David Dodd sees better deleveraging or stronger cash buildup than competitor.